Modena HIV Cohort, Università degli Studi di Modena
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mussini, Cristina
PETERPEN, NCT03671967: PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae

Recruiting
4
1084
Canada, RoW
Piperacillin/tazobactam, Meropenem
Rambam Health Care Campus, Rabin Medical Center, University of Modena and Reggio Emilia, Tel Aviv Medical Center, Meir Medical Center, Soroka University Medical Center, The Chaim Sheba Medical Center, McGill University Health Centre/Research Institute of the McGill University Health Centre, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Hadassah Medical Organization
Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia
01/26
04/26
EDOLAS, NCT04979468: Early DOlutegravir/LAmivudine Switching After Virological Suppression ( Study)

Recruiting
3
440
Europe
DOVATO, dolutegravir/lamivudine
Societa' Italiana Di Malattie Infettive E Tropicali
HIV-1-infection
04/23
04/24
MARIO, NCT05178862: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Not yet recruiting
2
26
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
NCT04090151: The RESPOND Outcomes Study

Recruiting
N/A
37853
Europe, RoW
Rigshospitalet, Denmark, Gilead Sciences, ViiV Healthcare
HIV
12/25
12/25
Chkhartishvili, Nikoloz
LIMT-2, NCT05070364: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals
Hepatitis Delta Virus
06/24
01/25
NCT04090151: The RESPOND Outcomes Study

Recruiting
N/A
37853
Europe, RoW
Rigshospitalet, Denmark, Gilead Sciences, ViiV Healthcare
HIV
12/25
12/25

Download Options